Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.41 |
| ▸ | KDM1A | O60341 | 4/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.37 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21035177 | 1.00 | SLC6A3 (0.41) | SLC6A3KDM1AATMSMN1; SMN2NPSR1 | |
| SCHEMBL22510391 | 0.86 | TSHR (0.38) | SLC6A3KDM1ANPSR1 | |
| SCHEMBL22495822 | 0.84 | HDAC4 (0.38) | SLC6A3KDM1ASMN1; SMN2NPSR1HDAC4 | |
| SCHEMBL21035178 | 0.84 | HDAC4 (0.38) | SLC6A3KDM1ASMN1; SMN2NPSR1HDAC4 | |
| SCHEMBL899999 | 0.73 | MAOB (0.41) | SLC6A3KDM1AHDAC4 | |
| SCHEMBL21035176 | 0.70 | HDAC1 (0.42) | KDM1AHDAC4 | |
| SCHEMBL22495785 | 0.70 | HDAC1 (0.42) | KDM1AHDAC4 | |
| SCHEMBL22495786 | 0.70 | HDAC1 (0.42) | KDM1AHDAC4 | |
| SCHEMBL15466643 | 0.70 | MAOB (0.41) | SLC6A3KDM1A | |
| SCHEMBL14379117 | 0.69 | HDAC2 (0.50) | SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11472788-B2 | Benzoimidazoles as selective inhibitors of indoleamine 2,3-dioxygenases | BEIGENE, LTD. (KY) | 2022-10-18 | — | — | US | disclosed |
| US-20200317638-A1 | NOVEL BENZOIMIDAZOLES AS SELECTIVE INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASES | BEONE MEDICINES I GMBH (CH) | 2020-10-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200317638-A1 | NOVEL BENZOIMIDAZOLES AS SELECTIVE INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASES | IDO2, IDO1, TPH2 | SLC6A3 343/4885KDM1A 128/4885ATM 3336/4885 |
| US-11472788-B2 | Benzoimidazoles as selective inhibitors of indoleamine 2,3-dioxygenases | IDO1, IDO2, TPH2 | SLC6A3 554/4885KDM1A 144/4885ATM 3662/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.